Citigroup
CTKB icon

Citigroup’s Cytek Biosciences CTKB Stock Holding History

Citigroup’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
56,130
+43,676
+351% +$186K ﹤0.01% 4228
2026
Q1 		$54.4K Sell
12,454
-9,709
-44% -$45.8K ﹤0.01% 4493
2025
Q4 		$112K Sell
22,163
-27,810
-56% -$129K ﹤0.01% 4271
2025
Q3 		$173K Sell
49,973
-59,670
-54% -$224K ﹤0.01% 4052
2025
Q2 		$373K Sell
109,643
-46,501
-30% -$155K ﹤0.01% 3784
2025
Q1 		$626K Sell
156,144
-4,051
-3% -$21K ﹤0.01% 3554
2024
Q4 		$1.04M Buy
160,195
+18,576
+13% +$111K ﹤0.01% 3338
2024
Q3 		$785K Buy
141,619
+64,563
+84% +$366K ﹤0.01% 3450
2024
Q2 		$430K Buy
77,056
+12,927
+20% +$77.6K ﹤0.01% 3488
2024
Q1 		$430K Buy
64,129
+3,075
+5% +$24.3K ﹤0.01% 3666
2023
Q4 		$557K Buy
61,054
+22,883
+60% +$144K ﹤0.01% 3328
2023
Q3 		$211K Sell
38,171
-31,805
-45% -$255K ﹤0.01% 3638
2023
Q2 		$598K Buy
69,976
+60,074
+607% +$539K ﹤0.01% 3243
2023
Q1 		$91K Buy
9,902
+7,384
+293% +$79.4K ﹤0.01% 4055
2022
Q4 		$25.7K Sell
2,518
-978
-28% -$13.1K ﹤0.01% 4504
2022
Q3 		$52K Sell
3,496
-5,603
-62% -$72.8K ﹤0.01% 4362
2022
Q2 		$97K Buy
9,099
+4,653
+105% +$46.3K ﹤0.01% 4237
2022
Q1 		$48K Buy
4,446
+275
+7% +$3.71K ﹤0.01% 4741
2021
Q4 		$68K Buy
4,171
+1,944
+87% +$40.7K ﹤0.01% 4929
2021
Q3 		$48K Buy
+2,227
New +$52.4K ﹤0.01% 4753

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup's CTKB Position: Q2 2026 in Review

Citigroup increased its Cytek Biosciences (CTKB) stake by 351% in Q2 2026, buying an estimated $186K and bringing the position to 56,130 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #4228.

Citigroup first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.04M in Q4 2024. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Citigroup held 56,130 shares of Cytek Biosciences worth $249K as of Q2 2026.
  • Citigroup bought 43,676 Cytek Biosciences shares in Q2 2026, an estimated $186K.
  • Cytek Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4228 holding.
  • Citigroup first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Citigroup's Cytek Biosciences position peaked at $1.04M in Q4 2024.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.